$85 Million

Molecular Partners AG

PIPE

Bookrunner, July 2020

Directed Share Issue

Molecular Partners is a clinical stage biopharmaceutical company applying its pioneering DARPin product engine to treat serious diseases, with an initial focus on oncology, immuno-oncology and ophthalmology. The Company’s DARPin technology consists of ankyrin repeat proteins, and the DARPin product engine allows the Company to build molecules with multiple modes of action to address complex biological problems, while potentially offering patients products that yield higher efficacy and fewer adverse events. The Company’s DARPin product candidates have the potential to become a novel class of drugs with broad therapeutic application and to overcome many of the limitations of conventional protein and antibody based therapeutics.